NCT06449209 2026-04-17
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
BioNTech SE
Phase 2 Active not recruiting
Clinical Trials
76 trialsNCT06500026 2026-04-17
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT03896503 2026-04-13
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05353439 2026-04-13
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05990738 2026-03-31
DAREONâ„¢-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05153239 2026-03-09
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
Phase 3 Active not recruiting
NCT07099898 2026-03-06
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Phase 3 Recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT07189455 2026-01-05
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Recruiting
NCT02514447 2025-09-25
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
G1 Therapeutics, Inc.
Phase 1/2 Completed
NCT05874401 2025-09-04
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Pharmacosmos A/S
Phase 4 Recruiting
NCT07106528 2025-08-06
Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2/3 Not yet recruiting
NCT07076095 2025-07-21
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2 Not yet recruiting
NCT06954246 2025-06-18
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03554473 2025-05-09
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02487095 2025-04-13
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT04514497 2025-03-06
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT06612151 2025-02-11
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT06498479 2024-10-16
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT04768296 2024-09-26
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
Phase 2 Completed
NCT01904253 2024-09-05
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT06581380 2024-09-03
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
JenKem Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT02200757 2024-06-25
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Completed
NCT06128837 2024-03-15
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT02649673 2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT00856037 2023-09-26
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer
University of Nebraska
Phase 1 Completed
NCT02963090 2023-02-15
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Terminated
NCT04022876 2022-10-10
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT03061812 2021-02-23
TAHOE
AbbVie
Phase 3 Completed
NCT03059667 2021-02-10
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT03227016 2021-01-27
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Central European Society for Anticancer Drug Research
Phase 1 Unknown
NCT03098030 2020-12-09
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
United Therapeutics
Phase 2/3 Completed
NCT01803269 2020-06-26
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Phase 2 Terminated
NCT00547651 2019-11-06
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Celgene
Phase 3 Completed
NCT04073550 2019-08-29
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT01497873 2018-12-27
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
Phase 2 Completed
NCT00098956 2018-07-23
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00287963 2018-05-17
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
Medical University of South Carolina
Phase 1 Completed
NCT00259935 2017-11-14
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02100007 2017-10-02
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
Phase 1/2 Terminated
NCT00828139 2017-08-21
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00043862 2017-05-31
(SCLC)
GlaxoSmithKline
Phase 2 Completed
NCT00046111 2017-05-30
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02980809 2016-12-02
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
First Hospitals affiliated to the China PLA General Hospital
Phase 2 Unknown